C52 CLINICAL EVALUATION AND BIOMARKERS OF PULMONARY HYPERTENSION I: Phosphodiesterase 5 (pde5) Inhibitors Potentiate Ut-15c (treprostinil)-Mediated Increases In Both Camp And Atp Release From Erythrocytes Of Humans With Pulmonary Arterial Hypertension (pah)